MESOBLAST LIMITED (MSB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MSB - MESOBLAST LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.71
Index: ASX300 | ALL-ORDS

Mesoblast is a Melbourne-headquartered medical research company investigating stem cell treatments and allogenic cellular medicines. The company was founded and listed in 2004.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.32

06 Dec
2023

0.005

OPEN

$0.32

1.59%

HIGH

$0.33

9,264,871

LOW

$0.32

TARGET
$0.58 81.3% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MSB: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 11.0 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-16.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx11.2 M
Book Value Per Share xxxxxxxxxxxxxxx92.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-103.0 M
Net Profit Margin xxxxxxxxxxxxxxx-1,091.71 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-16.49 %
Return on Invested Capital xxxxxxxxxxxxxxx-13.68 %
Return on Assets xxxxxxxxxxxxxxx-11.61 %
Return on Equity xxxxxxxxxxxxxxx-16.49 %
Return on Total Capital xxxxxxxxxxxxxxx-11.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-103.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx15 M
Long Term Debt xxxxxxxxxxxxxxx160 M
Total Debt xxxxxxxxxxxxxxx175 M
Goodwill - Gross xxxxxxxxxxxxxxx202 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx107 M
Price To Book Value xxxxxxxxxxxxxxx1.22

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx4.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx41 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx78 M
Research & Development xxxxxxxxxxxxxxx40 M
Investments - Total xxxxxxxxxxxxxxx3 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

22/09/2023

1

Upgrade to Speculative Buy from Hold

$0.58

81.25%

Mesoblast has met with the US FDA and provided clarity regarding the nature of the potency assay data that is now required, having confirmed the strategy for resubmission of a Biological Licence Application for Remestemcel-L in paediatric Graft versus Host Disease (GvHD).

Subsequent to the success of generating new data, Bell Potter is encouraged by the outcome of the meeting and estimates a submission could occur in the first quarter of 2024.

The broker makes no changes to earnings and valuation with the target unchanged at $0.58. Rating is upgraded to Speculative Buy from Hold based on the movement in the share price.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -11.02 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -9.66 cents.
Access Stockbroker Research History >

MSB STOCK CHART

FNArena News on MSB

1
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
2
Weekly Ratings, Targets, Forecast Changes – 22-09-23

Sep 25 2023 - Weekly Reports
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
FNArena Corporate Results Monitor – 04-09-2023

Sep 04 2023 - Australia
5
The Short Report – 24 Aug 2023

Aug 24 2023 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
2
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
3
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
4
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
5
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
6
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
7
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
8
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
10
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps